PMC:7556165 / 68749-69104 JSONTXT

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T385","span":{"begin":258,"end":263},"obj":"Species"}],"attributes":[{"id":"A385","pred":"ncbi_taxonomy_id","subj":"T385","obj":"NCBItxid:9606"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"replication, as well as severe lung injury. Potential therapeutic approaches include (Figure 10):\nFIGURE 10 Schematic representation of the potential therapeutic approaches to address ACE2 mediated infection. Exogenous administration of soluble recombinant human ACE 2 sequesters circulating viral particles, while specific ACE2 blockers bind the recepto"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T405","span":{"begin":44,"end":97},"obj":"Sentence"},{"id":"T406","span":{"begin":98,"end":209},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"replication, as well as severe lung injury. Potential therapeutic approaches include (Figure 10):\nFIGURE 10 Schematic representation of the potential therapeutic approaches to address ACE2 mediated infection. Exogenous administration of soluble recombinant human ACE 2 sequesters circulating viral particles, while specific ACE2 blockers bind the recepto"}

{"project":"LitCovid-sample-PD-UBERON","denotations":[{"id":"T148","span":{"begin":31,"end":35},"obj":"Body_part"}],"attributes":[{"id":"A148","pred":"uberon_id","subj":"T148","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"replication, as well as severe lung injury. Potential therapeutic approaches include (Figure 10):\nFIGURE 10 Schematic representation of the potential therapeutic approaches to address ACE2 mediated infection. Exogenous administration of soluble recombinant human ACE 2 sequesters circulating viral particles, while specific ACE2 blockers bind the recepto"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"1873","span":{"begin":31,"end":42},"obj":"Disease"},{"id":"1880","span":{"begin":185,"end":189},"obj":"Gene"},{"id":"1881","span":{"begin":264,"end":269},"obj":"Gene"},{"id":"1882","span":{"begin":325,"end":329},"obj":"Gene"},{"id":"1884","span":{"begin":258,"end":263},"obj":"Species"},{"id":"1885","span":{"begin":199,"end":208},"obj":"Disease"},{"id":"1959","span":{"begin":264,"end":269},"obj":"Gene"},{"id":"1964","span":{"begin":258,"end":263},"obj":"Species"}],"attributes":[{"id":"A1964","pred":"pubann:denotes","subj":"1964","obj":"Tax:9606"},{"id":"A1881","pred":"pubann:denotes","subj":"1881","obj":"Gene:59272"},{"id":"A1882","pred":"pubann:denotes","subj":"1882","obj":"Gene:59272"},{"id":"A1885","pred":"pubann:denotes","subj":"1885","obj":"MESH:D007239"},{"id":"A1959","pred":"pubann:denotes","subj":"1959","obj":"Gene:59272"},{"id":"A1884","pred":"pubann:denotes","subj":"1884","obj":"Tax:9606"},{"id":"A1880","pred":"pubann:denotes","subj":"1880","obj":"Gene:59272"},{"id":"A1873","pred":"pubann:denotes","subj":"1873","obj":"MESH:D055370"}],"text":"replication, as well as severe lung injury. Potential therapeutic approaches include (Figure 10):\nFIGURE 10 Schematic representation of the potential therapeutic approaches to address ACE2 mediated infection. Exogenous administration of soluble recombinant human ACE 2 sequesters circulating viral particles, while specific ACE2 blockers bind the recepto"}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T6121","span":{"begin":185,"end":189},"obj":"Protein"},{"id":"T6122","span":{"begin":264,"end":267},"obj":"Protein"},{"id":"T6147","span":{"begin":325,"end":329},"obj":"Protein"}],"attributes":[{"id":"A6121","pred":"uniprot_id","subj":"T6121","obj":"https://www.uniprot.org/uniprot/Q9UFZ6"},{"id":"A6122","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/Q9GLN7"},{"id":"A6123","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/Q9GLN6"},{"id":"A6124","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/Q9EQM9"},{"id":"A6125","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/Q8CFN1"},{"id":"A6126","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/Q7TMC6"},{"id":"A6127","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/Q7M4L4"},{"id":"A6128","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/Q6GTS2"},{"id":"A6129","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/Q59GY8"},{"id":"A6130","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/Q53YX9"},{"id":"A6131","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/Q50JE5"},{"id":"A6132","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/Q10751"},{"id":"A6133","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/Q0GA41"},{"id":"A6134","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/P47820"},{"id":"A6135","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/P22968"},{"id":"A6136","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/P22967"},{"id":"A6137","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/P22966"},{"id":"A6138","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/P12822"},{"id":"A6139","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/P12821"},{"id":"A6140","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/P12820"},{"id":"A6141","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/P09470"},{"id":"A6142","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/O02852"},{"id":"A6143","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/E7EU16"},{"id":"A6144","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/B4DXI3"},{"id":"A6145","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/B0LPF0"},{"id":"A6146","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/Q9VJV3"},{"id":"A6147","pred":"uniprot_id","subj":"T6147","obj":"https://www.uniprot.org/uniprot/Q9UFZ6"}],"text":"replication, as well as severe lung injury. Potential therapeutic approaches include (Figure 10):\nFIGURE 10 Schematic representation of the potential therapeutic approaches to address ACE2 mediated infection. Exogenous administration of soluble recombinant human ACE 2 sequesters circulating viral particles, while specific ACE2 blockers bind the recepto"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T276","span":{"begin":0,"end":11},"obj":"http://purl.obolibrary.org/obo/IDO_0000608"},{"id":"T277","span":{"begin":199,"end":208},"obj":"http://purl.obolibrary.org/obo/IDO_0000586"}],"text":"replication, as well as severe lung injury. Potential therapeutic approaches include (Figure 10):\nFIGURE 10 Schematic representation of the potential therapeutic approaches to address ACE2 mediated infection. Exogenous administration of soluble recombinant human ACE 2 sequesters circulating viral particles, while specific ACE2 blockers bind the recepto"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T450","span":{"begin":31,"end":35},"obj":"Body_part"}],"attributes":[{"id":"A450","pred":"fma_id","subj":"T450","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"replication, as well as severe lung injury. Potential therapeutic approaches include (Figure 10):\nFIGURE 10 Schematic representation of the potential therapeutic approaches to address ACE2 mediated infection. Exogenous administration of soluble recombinant human ACE 2 sequesters circulating viral particles, while specific ACE2 blockers bind the recepto"}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T405","span":{"begin":36,"end":42},"obj":"Disease"},{"id":"T406","span":{"begin":199,"end":208},"obj":"Disease"}],"attributes":[{"id":"A405","pred":"mondo_id","subj":"T405","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A406","pred":"mondo_id","subj":"T406","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"replication, as well as severe lung injury. Potential therapeutic approaches include (Figure 10):\nFIGURE 10 Schematic representation of the potential therapeutic approaches to address ACE2 mediated infection. Exogenous administration of soluble recombinant human ACE 2 sequesters circulating viral particles, while specific ACE2 blockers bind the recepto"}

{"project":"LitCovid-sample-PD-MAT","denotations":[{"id":"T134","span":{"begin":31,"end":35},"obj":"http://purl.obolibrary.org/obo/MAT_0000135"}],"text":"replication, as well as severe lung injury. Potential therapeutic approaches include (Figure 10):\nFIGURE 10 Schematic representation of the potential therapeutic approaches to address ACE2 mediated infection. Exogenous administration of soluble recombinant human ACE 2 sequesters circulating viral particles, while specific ACE2 blockers bind the recepto"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1873","span":{"begin":31,"end":42},"obj":"Disease"},{"id":"1880","span":{"begin":185,"end":189},"obj":"Gene"},{"id":"1881","span":{"begin":264,"end":269},"obj":"Gene"},{"id":"1882","span":{"begin":325,"end":329},"obj":"Gene"},{"id":"1884","span":{"begin":258,"end":263},"obj":"Species"},{"id":"1885","span":{"begin":199,"end":208},"obj":"Disease"}],"attributes":[{"id":"A1873","pred":"tao:has_database_id","subj":"1873","obj":"MESH:D055370"},{"id":"A1880","pred":"tao:has_database_id","subj":"1880","obj":"Gene:59272"},{"id":"A1881","pred":"tao:has_database_id","subj":"1881","obj":"Gene:59272"},{"id":"A1882","pred":"tao:has_database_id","subj":"1882","obj":"Gene:59272"},{"id":"A1884","pred":"tao:has_database_id","subj":"1884","obj":"Tax:9606"},{"id":"A1885","pred":"tao:has_database_id","subj":"1885","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"replication, as well as severe lung injury. Potential therapeutic approaches include (Figure 10):\nFIGURE 10 Schematic representation of the potential therapeutic approaches to address ACE2 mediated infection. Exogenous administration of soluble recombinant human ACE 2 sequesters circulating viral particles, while specific ACE2 blockers bind the recepto"}

{"project":"LitCovid-sentences","denotations":[{"id":"T405","span":{"begin":44,"end":97},"obj":"Sentence"},{"id":"T406","span":{"begin":98,"end":209},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"replication, as well as severe lung injury. Potential therapeutic approaches include (Figure 10):\nFIGURE 10 Schematic representation of the potential therapeutic approaches to address ACE2 mediated infection. Exogenous administration of soluble recombinant human ACE 2 sequesters circulating viral particles, while specific ACE2 blockers bind the recepto"}